Coral González Martínez, Stavros Therapontos, Jose A Lorente, Miriam Alcaide Lucena, F Gabriel Ortega, M Jose Serrano
{"title":"Evaluating MicroRNAs as diagnostic tools for lymph node metastasis in breast cancer: Findings from a systematic review and meta-analysis.","authors":"Coral González Martínez, Stavros Therapontos, Jose A Lorente, Miriam Alcaide Lucena, F Gabriel Ortega, M Jose Serrano","doi":"10.1016/j.critrevonc.2024.104598","DOIUrl":null,"url":null,"abstract":"<p><p>Lymph node metastasis (LNM) significantly affects the prognosis and clinical management of breast cancer (BC) patients. This systematic review and meta-analysis aim to identify microRNAs (miRNAs) associated with LNM in BC and evaluate their potential diagnostic and prognostic value. Following PRISMA guidelines, a comprehensive literature search was conducted in PubMed, Web of Science, and SCOPUS databases, to assess the role of miRNAs in LNM BC. The Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool was used to evaluate the quality of included studies. A total of 84 miRNAs were identified as differentially expressed in BC patients with LNM. Of these, a meta-analysis was performed in two microRNAs that were present in at least 3 different articles with a coherent expression direction: miR-155 and miR-34a. The meta-analysis returned a pooled a Log2 fold change of 1.50 for miR-155 (upregulated) and -0.53 for miR-34a (downregulated) with no evidence of publication bias, and a low risk of bias and applicability concerns. To conclude, this study names miR-155 and miR-34a as potential diagnostic biomarkers for LNM in BC, although further experimental validation is necessary to confirm these findings and develop non-invasive diagnostic tools for clinical use.</p>","PeriodicalId":93958,"journal":{"name":"Critical reviews in oncology/hematology","volume":" ","pages":"104598"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical reviews in oncology/hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.critrevonc.2024.104598","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Lymph node metastasis (LNM) significantly affects the prognosis and clinical management of breast cancer (BC) patients. This systematic review and meta-analysis aim to identify microRNAs (miRNAs) associated with LNM in BC and evaluate their potential diagnostic and prognostic value. Following PRISMA guidelines, a comprehensive literature search was conducted in PubMed, Web of Science, and SCOPUS databases, to assess the role of miRNAs in LNM BC. The Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool was used to evaluate the quality of included studies. A total of 84 miRNAs were identified as differentially expressed in BC patients with LNM. Of these, a meta-analysis was performed in two microRNAs that were present in at least 3 different articles with a coherent expression direction: miR-155 and miR-34a. The meta-analysis returned a pooled a Log2 fold change of 1.50 for miR-155 (upregulated) and -0.53 for miR-34a (downregulated) with no evidence of publication bias, and a low risk of bias and applicability concerns. To conclude, this study names miR-155 and miR-34a as potential diagnostic biomarkers for LNM in BC, although further experimental validation is necessary to confirm these findings and develop non-invasive diagnostic tools for clinical use.
淋巴结转移(LNM)显著影响乳腺癌(BC)患者的预后和临床管理。本系统综述和荟萃分析旨在鉴定与BC中LNM相关的microrna (mirna),并评估其潜在的诊断和预后价值。遵循PRISMA指南,在PubMed、Web of Science和SCOPUS数据库中进行了全面的文献检索,以评估mirna在LNM BC中的作用。使用诊断准确性研究质量评估(QUADAS-2)工具评估纳入研究的质量。在BC合并LNM的患者中,共有84个mirna被鉴定为差异表达。其中,对至少出现在3篇不同文章中具有一致表达方向的两个microrna进行了荟萃分析:miR-155和miR-34a。荟萃分析得出miR-155(上调)的Log2倍变化为1.50,miR-34a(下调)的Log2倍变化为-0.53,无发表偏倚证据,偏倚风险低,适用性问题。总之,本研究将miR-155和miR-34a命名为卑诗省LNM的潜在诊断生物标志物,尽管需要进一步的实验验证来证实这些发现并开发用于临床使用的非侵入性诊断工具。